<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med</journal-id><journal-id journal-id-type="iso-abbrev">Intensive Care Med</journal-id><journal-title-group><journal-title>Intensive Care Medicine</journal-title></journal-title-group><issn pub-type="ppub">0342-4642</issn><issn pub-type="epub">1432-1238</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29632995</article-id><article-id pub-id-type="pmc">5924663</article-id><article-id pub-id-type="publisher-id">5143</article-id><article-id pub-id-type="doi">10.1007/s00134-018-5143-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Seven-Day Profile Publication</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Welte</surname><given-names>Tobias</given-names></name><address><phone>+49-511-532-3531</phone><phone>+49-511-532-3530</phone><email>Welte.Tobias@mh-hannover.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dellinger</surname><given-names>R. Phillip</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ebelt</surname><given-names>Henning</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ferrer</surname><given-names>Miguel</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Opal</surname><given-names>Steven M.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Singer</surname><given-names>Mervyn</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Vincent</surname><given-names>Jean-Louis</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Werdan</surname><given-names>Karl</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Martin-Loeches</surname><given-names>Ignacio</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Almirall</surname><given-names>Jordi</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Artigas</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Ignacio Ayestar&#x000e1;n</surname><given-names>Jose</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Nuding</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ferrer</surname><given-names>Ricard</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Sirgo Rodr&#x000ed;guez</surname><given-names>Gonzalo</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Shankar-Hari</surname><given-names>Manu</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>&#x000c1;lvarez-Lerma</surname><given-names>Francisco</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Riessen</surname><given-names>Reimer</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Sirvent</surname><given-names>Josep-Maria</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Kluge</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Zacharowski</surname><given-names>Kai</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Bonastre Mora</surname><given-names>Juan</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name><surname>Lapp</surname><given-names>Harald</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>W&#x000f6;bker</surname><given-names>Gabriele</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name><surname>Achtzehn</surname><given-names>Ute</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Brealey</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Kempa</surname><given-names>Axel</given-names></name><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name><surname>S&#x000e1;nchez Garc&#x000ed;a</surname><given-names>Miguel</given-names></name><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name><surname>Brederlau</surname><given-names>J&#x000f6;rg</given-names></name><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><name><surname>Kochanek</surname><given-names>Matthias</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><name><surname>Reschreiter</surname><given-names>Henrik Peer</given-names></name><xref ref-type="aff" rid="Aff29">29</xref></contrib><contrib contrib-type="author"><name><surname>Wise</surname><given-names>Matthew P.</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name><surname>Belohradsky</surname><given-names>Bernd H.</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Bobenhausen</surname><given-names>Iris</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>D&#x000e4;lken</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Dubovy</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Langohr</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Mayer</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Sch&#x000fc;ttrumpf</surname><given-names>J&#x000f6;rg</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Wartenberg-Demand</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Wippermann</surname><given-names>Ulrike</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Wolf</surname><given-names>Daniele</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Torres</surname><given-names>Antoni</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9529 9877</institution-id><institution-id institution-id-type="GRID">grid.10423.34</institution-id><institution>Department of Pneumology and German Center for Lung Research (DZL), </institution><institution>Hannover Medical School, </institution></institution-wrap>Carl-Neuberg-Str. 1, 30625 Hannover, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0384 9827</institution-id><institution-id institution-id-type="GRID">grid.411896.3</institution-id><institution>Department of Medicine, Cooper Medical School of Rowan University, </institution><institution>Cooper University Health Care, </institution></institution-wrap>Camden, NJ USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0390 1701</institution-id><institution-id institution-id-type="GRID">grid.461820.9</institution-id><institution>Klinik und Poliklinik f&#x000fc;r Innere Medizin III, </institution><institution>Universit&#x000e4;tsklinikum Halle (Saale), </institution></institution-wrap>Halle (Saale), Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0247</institution-id><institution-id institution-id-type="GRID">grid.5841.8</institution-id><institution>Department of Pneumology, Respiratory Institute, Hospital Clinic of Barcelona, IDIBAPS, CibeRes (CB06/06/0028), </institution><institution>University of Barcelona, </institution></institution-wrap>Barcelona, Spain </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9094</institution-id><institution-id institution-id-type="GRID">grid.40263.33</institution-id><institution>Infectious Disease Division, Rhode Island Hospital, </institution><institution>Alpert Medical School of Brown University, </institution></institution-wrap>Providence, RI USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution>Bloomsbury Institute of Intensive Care Medicine, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2348 0746</institution-id><institution-id institution-id-type="GRID">grid.4989.c</institution-id><institution>Department of Intensive Care, Erasme University Hospital, </institution><institution>Universit&#x000e9; Libre de Bruxelles, </institution></institution-wrap>Brussels, Belgium </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0617 8280</institution-id><institution-id institution-id-type="GRID">grid.416409.e</institution-id><institution>Present Address: Multidisciplinary Intensive Care Research Organization (MICRO) Wellcome Trust &#x02013; HRB Clinical Research Facility (CRF) at St. James&#x02019;s Hospital, </institution><institution>Trinity Centre for Health Sciences, </institution></institution-wrap>Dublin, Ireland </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.7080.f</institution-id><institution>Critical Care Center, CIBER Enfermedades Respiratorias, Corporaci&#x000f3; Sanitaria Universitaria Parc Tauli, </institution><institution>Autonomous University of Barcelona, </institution></institution-wrap>Sabadell, Spain </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.7080.f</institution-id><institution>Unitat de Cures Intensives, Hospital de Matar&#x000f3;, </institution><institution>Universitat Aut&#x000f3;noma de Barcelona, </institution></institution-wrap>Matar&#x000f3;, Barcelona Spain </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1796 5984</institution-id><institution-id institution-id-type="GRID">grid.411164.7</institution-id><institution>Unidad de Cuidados Intensivos, </institution><institution>Hospital Universitario Son Espases, </institution></institution-wrap>Palma de Mallorca, Spain </aff><aff id="Aff12"><label>12</label>Hospital Universitario M&#x000fa;tua de Terrassa, SODIR-VHIR Research Group, Barcelona, Spain </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2284 9230</institution-id><institution-id institution-id-type="GRID">grid.410367.7</institution-id><institution>Intensive Care Unit, Hospital Universitario Joan XXIII, Instituto de Investigaci&#x000f3;n Sanitaria Pere Virgili, </institution><institution>Rovira i Virgili University, </institution></institution-wrap>Tarragona, Spain </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.420545.2</institution-id><institution>Intensive Care Medicine, </institution><institution>Guy&#x02019;s and St. Thomas&#x02019; NHS Foundation Trust, </institution></institution-wrap>London, UK </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1767 8811</institution-id><institution-id institution-id-type="GRID">grid.411142.3</institution-id><institution>Servicio de Medicina Intensiva, </institution><institution>Hospital del Mar, </institution></institution-wrap>Barcelona, Spain </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0196 8249</institution-id><institution-id institution-id-type="GRID">grid.411544.1</institution-id><institution>Universit&#x000e4;tsklinikum T&#x000fc;bingen, Internistische Intensivstation, </institution></institution-wrap>T&#x000fc;bingen, Germany </aff><aff id="Aff17"><label>17</label>Servicio de Medicina Intensiva, Hospital U. Girona Dr. Josep Trueta, Avinguda Fran&#x000e7;a, Girona, Spain </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2180 3484</institution-id><institution-id institution-id-type="GRID">grid.13648.38</institution-id><institution>Klinik f&#x000fc;r Intensivmedizin, </institution><institution>Universit&#x000e4;tsklinikum Hamburg-Eppendorf, </institution></institution-wrap>Hamburg, Germany </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0578 8220</institution-id><institution-id institution-id-type="GRID">grid.411088.4</institution-id><institution>Klinik f&#x000fc;r An&#x000e4;sthesiologie, Intensivmedizin und Schmerztherapie, </institution><institution>Universit&#x000e4;tsklinikum Frankfurt, </institution></institution-wrap>Frankfurt, Germany </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0360 9602</institution-id><institution-id institution-id-type="GRID">grid.84393.35</institution-id><institution>Servicio de Cuidados Intensivos Adultos, </institution><institution>Hospital Universitari y Polit&#x000e8;cnico La Fe, </institution></institution-wrap>Valencia, Spain </aff><aff id="Aff21"><label>21</label>3 Medizinische Klinik, Kardiologie und Intensivmedizin, Helios Klinikum Erfurt, Erfurt, Germany </aff><aff id="Aff22"><label>22</label>Klinik f&#x000fc;r Intensivmedizin, Helios Universit&#x000e4;tsklinikum Wuppertal, Wuppertal, Germany </aff><aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0389 4214</institution-id><institution-id institution-id-type="GRID">grid.459629.5</institution-id><institution>Innere Medizin IV &#x02013; Pneumologie, </institution><institution>Klinikum Chemnitz gGmbH, </institution></institution-wrap>Chemnitz, Germany </aff><aff id="Aff24"><label>24</label>Critical Care Unit, NIHR University College London Hospitals Biomedical Research Centre, University College London Hospitals, NHS Foundation Trust, London, UK </aff><aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0493 2358</institution-id><institution-id institution-id-type="GRID">grid.459701.e</institution-id><institution>Klinik f&#x000fc;r Allgemeine Innere Medizin, </institution><institution>Katharinenhospital, </institution></institution-wrap>Stuttgart, Germany </aff><aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0671 5785</institution-id><institution-id institution-id-type="GRID">grid.411068.a</institution-id><institution>Servicio de Medicina Intensiva, </institution><institution>Hospital Cl&#x000ed;nico San Carlos, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff27"><label>27</label>Helios Klinikum Berlin-Buch, Klinik f&#x000fc;r Intensivmedizin, Berlin, Germany </aff><aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8852 305X</institution-id><institution-id institution-id-type="GRID">grid.411097.a</institution-id><institution>Department I of Internal Medicine, Intensive Care Unit and Hemostasis, </institution><institution>University Hospital of Cologne, </institution></institution-wrap>Cologne, Germany </aff><aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0455 6778</institution-id><institution-id institution-id-type="GRID">grid.412940.a</institution-id><institution>Poole Hospital NHS Foundation Trust, </institution></institution-wrap>Poole, Dorset UK </aff><aff id="Aff30"><label>30</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0169 7725</institution-id><institution-id institution-id-type="GRID">grid.241103.5</institution-id><institution>Critical Care Unit, </institution><institution>University Hospital of Wales, </institution></institution-wrap>Heath Park, Cardiff, UK </aff><aff id="Aff31"><label>31</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution>University Children&#x02019;s Hospital Munich, </institution><institution>Ludwig-Maximilians University Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff32"><label>32</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0408 4598</institution-id><institution-id institution-id-type="GRID">grid.420058.b</institution-id><institution>Biotest AG, </institution></institution-wrap>Dreieich, Germany </aff><aff id="Aff33"><label>33</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0247</institution-id><institution-id institution-id-type="GRID">grid.5841.8</institution-id><institution>Servei de Pneumologia, Hospital Cl&#x000ed;nic, </institution><institution>Universitat de Barcelona IDIBAPS, CIBERES, </institution></institution-wrap>Barcelona, Spain </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>9</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="ppub"><year>2018</year></pub-date><volume>44</volume><issue>4</issue><fpage>438</fpage><lpage>448</lpage><history><date date-type="received"><day>10</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>17</day><month>3</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">The CIGMA study investigated a novel human polyclonal antibody preparation (trimodulin) containing&#x02009;~&#x02009;23% immunoglobulin (Ig) M,&#x02009;~&#x02009;21% IgA, and&#x02009;~&#x02009;56% IgG as add-on therapy for patients with severe community-acquired pneumonia (sCAP).</p></sec><sec><title>Methods</title><p id="Par2">In this double-blind, phase&#x000a0;II study (NCT01420744), 160 patients with sCAP requiring invasive mechanical ventilation were randomized (1:1) to trimodulin (42&#x000a0;mg&#x000a0;IgM/kg/day) or placebo for five consecutive days. Primary endpoint was ventilator-free days (VFDs). Secondary endpoints included 28-day all-cause and pneumonia-related mortality. Safety and tolerability were monitored. Exploratory post hoc analyses were performed in subsets stratified by baseline C-reactive protein (CRP;&#x02009;&#x02265;&#x02009;70&#x000a0;mg/L) and/or IgM (&#x02264;&#x02009;0.8&#x000a0;g/L).</p></sec><sec><title>Results</title><p id="Par3">Overall, there was no statistically significant difference in VFDs between trimodulin (mean 11.0, median 11 [<italic>n&#x02009;</italic>=&#x02009;81]) and placebo (mean 9.6; median 8 [<italic>n&#x02009;</italic>=&#x02009;79]; <italic>p&#x02009;</italic>=&#x02009;0.173). Twenty-eight-day all-cause mortality was 22.2% vs. 27.8%, respectively (<italic>p&#x02009;</italic>=&#x02009;0.465). Time to discharge from intensive care unit and mean duration of hospitalization were comparable between groups. Adverse-event incidences were comparable. Post hoc subset analyses, which included the majority of patients (58&#x02013;78%), showed significant reductions in all-cause mortality (trimodulin vs. placebo) in patients with high CRP, low IgM, and high CRP/low IgM at baseline.</p></sec><sec><title>Conclusions</title><p id="Par4">No significant differences were found in VFDs and mortality between trimodulin and placebo groups. Post hoc analyses supported improved outcome regarding mortality with trimodulin in subsets of patients with elevated CRP, reduced IgM, or both. These findings warrant further investigation.</p><p>Trial registration: NCT01420744.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1007/s00134-018-5143-7) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Trimodulin</kwd><kwd>Polyclonal antibody</kwd><kwd>Severe community-acquired pneumonia</kwd><kwd>Add-on therapy</kwd><kwd>Immunoglobulin M</kwd></kwd-group><funding-group><award-group><funding-source><institution>Biotest AG</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature and ESICM 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="FPar1"><title>Take-home message</title><p id="Par5">
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="2">In mechanically ventilated patients with severe community-acquired pneumonia, add-on therapy with trimodulin, a novel polyclonal antibody preparation, did not statistically significantly increase ventilator-free days (primary endpoint) vs. placebo. Exploratory post hoc analyses suggest reductions in mortality for trimodulin compared with placebo in subsets of patients with elevated C-reactive protein levels and/or reduced immunoglobulin M levels, and warrant investigation in a phase III study with a targeted patient population.</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par6">Community-acquired pneumonia (CAP) has an incidence of ~&#x02009;1.2 per 1000 persons per year in Europe, varying with region, age, and comorbidities [<xref ref-type="bibr" rid="CR1">1</xref>]. Up to 21% of hospitalized patients with CAP are admitted to intensive care units (ICUs), thus impacting healthcare costs and clinical outcomes [<xref ref-type="bibr" rid="CR2">2</xref>]. Severe CAP (sCAP), usually defined as CAP that requires treatment in an ICU, is associated with high mortality of up to 58% [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par7">Antibiotic therapy with supportive care alone has limited success in sCAP; hence, targeting inflammatory responses may improve patient outcomes. This approach is supported by the observation that a systemic and complex cytokine response (interleukin-6 and -10) is linked to greater mortality in patients with CAP, irrespective of the presence of sepsis [<xref ref-type="bibr" rid="CR4">4</xref>]. Further, therapeutic response and treatment outcomes in acute respiratory distress syndrome may be worse in patients with a hyperinflammatory disease phenotype [<xref ref-type="bibr" rid="CR5">5</xref>]. A recombinant tissue factor pathway inhibitor, activated protein C, corticosteroids, intravenous immunoglobulins (Igs), and intravenous IgM-enriched Igs have been investigated for their potential as add-on therapies targeted at the immune response in patients with sCAP [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par8">IgM plays a critical role in the immediate defense against severe bacterial infection. Reduced IgM levels have been observed in patients with CAP, sepsis, and severe pandemic influenza; consequently, interest in add-on therapy with IgM-enriched preparations has increased [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. The evidence for IgM-enriched Ig preparations in patients with severe sepsis and septic shock is incompletely understood, although systematic reviews have generally concluded that IgM-enriched Ig preparations are associated with a reduction in mortality [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Relevant mechanisms of action include opsonization of causal pathogens, neutralization of microbial pathogens and virulence factors, and modulation of the inflammatory response [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par9">Trimodulin is a novel human plasma-derived native polyclonal antibody preparation for intravenous administration [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Trimodulin contains IgM (~&#x02009;23%), IgA (~&#x02009;21%), and IgG (~&#x02009;56%).</p><p id="Par10">The CIGMA (Concentrated IgM for Application) study reported here aimed to evaluate the efficacy and safety of trimodulin as an add-on therapy in patients with sCAP requiring invasive mechanical ventilation (IMV).</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study design and patient population</title><p id="Par11">The CIGMA study (NCT01420744 [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]), a randomized, placebo-controlled, double-blind, multicenter, parallel-group, phase II trial, was conducted in hospitals in Germany, Spain, and the UK. The study was conducted in accordance with the International Council for Harmonisation, Good Clinical Practice standards, and the Declaration of Helsinki, and with local institutional review board/independent ethics committee approval. All patients (or their representatives) provided written informed consent.</p><p id="Par12">Patients&#x02009;&#x02265;&#x02009;18&#x000a0;years of age with sCAP (diagnosed clinically and radiologically), requiring IMV and receiving standard antibiotics, were enrolled. Patients with suspected hospital-acquired pneumonia; severe lung diseases interfering with sCAP therapy (e.g., cystic fibrosis); life expectancy of &#x02264;&#x02009;28&#x000a0;days due to medical conditions not related to sCAP or to sCAP-associated sepsis; selective, absolute IgA deficiency with antibodies to IgA, neutrophil count &#x0003c;&#x02009;1000/mm<sup>3</sup>; or platelet count &#x0003c;&#x02009;50,000/mm<sup>3</sup> were excluded. Study-specific guidance on IMV, weaning procedures based on the concept of lung-protective ventilation, and on antibiotic treatment according to the Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of CAP in adults was provided to minimize potential differences among sites and countries [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par13">Eligible patients were randomized 1:1 to receive either trimodulin (5% protein solution; BT086; Biotest AG, Dreieich, Germany) or an equal volume of human albumin as placebo (1% protein solution), both as intravenous infusion. Dosing of trimodulin based on IgM content (42&#x000a0;mg&#x000a0;IgM/kg body weight) or placebo was once daily for five consecutive days. Infusion was initiated &#x02265;&#x02009;1 and &#x02264;&#x02009;12&#x000a0;h following commencement of IMV at a rate of 0.1&#x000a0;mL/min, increasing by 0.1 mL every 10&#x000a0;min to a maximum of 0.5&#x000a0;mL/min (target infusion rate).</p><p id="Par14">Patients were followed until day&#x000a0;28 or hospital discharge, whichever occurred first (with an additional safety follow-up visit at day 43 in the UK). Mortality was followed up until day 28 in discharged patients.</p><p id="Par15">Patients were assigned a unique randomization number generated by Accovion GmbH (Eschborn, Germany; now Clinipace Worldwide, Morrisville, North Carolina, USA) using Rando<sup>&#x000ae;</sup> and recorded by the investigator. Randomization numbers were grouped in blocks of four to facilitate equal distribution into the two groups. Blinding was maintained by a similar appearance of placebo to trimodulin, and vials were covered with transparent colored foil.</p><p id="Par16">Pathogen detection was performed according to local standards, with sputum and blood cultures being the most frequently analyzed, followed by smear and bronchoalveolar lavage.</p></sec><sec id="Sec4"><title>Efficacy assessments</title><p id="Par17">The primary endpoint was ventilator-free days (VFDs), defined as the number of days between extubation from IMV to day&#x000a0;28 after enrollment. VFDs were set to &#x0201c;0&#x0201d; if the patient died before day&#x000a0;28 or required IMV for&#x02009;&#x02265;&#x02009;28&#x000a0;days [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par18">Secondary endpoints included 28-day all-cause mortality, 28-day investigator-determined pneumonia-related mortality, time from admission to discharge from the ICU, time from hospital admission to discharge, change in Sequential Organ Failure Assessment (SOFA) score (measured on days 1 and 28), and days free from inotrope/vasopressor (dobutamine, epinephrine, dopamine, or norepinephrine).</p></sec><sec id="Sec5"><title>Safety</title><p id="Par19">Safety was assessed throughout the trial, with events classified using the Medical Dictionary for Regulatory Activities (MedDRA) version 17.1. Treatment-emergent adverse events (TEAEs; defined as an adverse event [AE] that occurred from the time of first dose of study medication until the final follow-up visit, independent of relation to study drug), infusion-related reactions (defined as TEAEs that occurred during or within 24&#x000a0;h after infusion of study medication), vital signs, electrocardiograms, and laboratory parameters including clinical chemistry, hematology, and coagulation were recorded. Renal function was monitored through serum creatinine. Estimated glomerular filtration rate was calculated post hoc using the Chronic Kidney Disease Epidemiology Collaboration equation considering serum creatinine, age, gender, and race [<xref ref-type="bibr" rid="CR22">22</xref>]. An independent data and safety monitoring board (DSMB) closely monitored the first six sequentially enrolled patients. The DSMB also reviewed unblinded safety data of patients during the course of the study.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par20">All statistical methods, unless otherwise specified, were prespecified in the study protocol.</p><p id="Par21">A group-sequential adaptive design was chosen that allowed modifications, such as sample size re-estimation or planning of further analyses based on interim results. After the first of two interim analyses, the sample size was adjusted to 160 patients [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par22">VFDs were evaluated using a one-sided Wilcoxon&#x02013;Mann&#x02013;Whitney test with an &#x003b1; level of 0.025. Twenty-eight-day all-cause mortality was evaluated using the Kaplan&#x02013;Meier method and analyzed using a Mantel&#x02013;Haenszel test. The study was powered to detect a difference of two VFDs between the treatment arms.</p><p id="Par23">Efficacy analyses were performed in the intent-to-treat set, which included all randomized patients who received at least one dose of study drug and at least one efficacy assessment, assigned as randomized. Safety analyses were performed using the safety set, which comprised all patients who received at least one dose of study drug according to medication received, regardless of randomization.</p><p id="Par24">Exploratory post hoc analyses were performed to identify patient subsets that may benefit most from trimodulin treatment. Subsets with a high mortality delta (defined as the difference between the percentage of patients who received trimodulin and died, and the percentage of patients who received placebo and died) were considered for further analyses (if the subsets were of sufficient size). Markers were selected taking into account the possible targeting of the inflammatory response or immunomodulatory capacity of trimodulin [<xref ref-type="bibr" rid="CR23">23</xref>]. C-reactive protein (CRP) and IgM cutoff values were chosen to identify maximal differences between the trimodulin and placebo groups (Supplementary Figs.&#x000a0;S1 and S2). Four subsets were identified for use in the post hoc analyses: patients with baseline levels of &#x02265;&#x02009;70&#x000a0;mg/L CRP (high CRP),&#x02009;&#x02264;&#x02009;0.8&#x000a0;g/L IgM (low IgM), CRP&#x02009;&#x02265;&#x02009;70&#x000a0;mg/L and&#x02009;&#x02264;&#x02009;0.8&#x000a0;g/L IgM (combined high CRP/low IgM), and&#x02009;&#x02265;&#x02009;2&#x000a0;ng/mL procalcitonin (high procalcitonin [PCT]). For statistical methods and sample size calculation, refer to the Supplementary Methods.</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><p id="Par25">A total of 161 eligible patients were enrolled (from 24/41 sites [Germany, 10; Spain, 10; and UK, 4]) between October 4, 2011 and February 25, 2015; 160 patients were randomized (81 trimodulin; 79 placebo) and received at least one dose of study medication in addition to antibiotic treatment. Patient disposition is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Patient disposition and reasons for discontinuation during the study period</p></caption><graphic xlink:href="134_2018_5143_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par26">No significant differences in patient demographics and other baseline characteristics (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) were identified between the treatment groups except for higher PCT levels and higher Acute Physiology and Chronic Health Evaluation (APACHE) II values in the placebo group. These higher levels of PCT at baseline were partially due to outliers (median 8.7, interquartile range [IQR] 1.9&#x02013;30.6&#x000a0;ng/mL). Common comorbidities included hypertension, cardiac disorders, renal/urinary disorders, and nervous system disorders in both groups.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Demographics and other baseline characteristics in all patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">Trimodulin (<italic>n</italic>&#x02009;=&#x02009;81)</th><th align="left">Placebo (<italic>n</italic>&#x02009;=&#x02009;79)</th><th align="left"><italic>p</italic> value*</th></tr></thead><tbody><tr><td align="left">Sex, <italic>n</italic> (%)</td><td align="left"/><td align="left"/><td char="." align="char">0.675</td></tr><tr><td align="left">&#x000a0;&#x000a0;Male</td><td align="left">56 (69.1)</td><td align="left">57 (72.2)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;Female</td><td align="left">25 (30.9)</td><td align="left">22 (27.8)</td><td align="left"/></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Mean (SD)</th><th align="left">Median (IQR)</th><th align="left">Mean (SD)</th><th align="left">Median (IQR)</th><th align="left"/></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">63.7 (14.5)</td><td align="left">66 (53&#x02013;75)</td><td align="left">65.5 (14.8)</td><td align="left">67 (57&#x02013;77)</td><td char="." align="char">0.435</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)<sup>a</sup></td><td align="left">26.5 (5.0)</td><td align="left">25.7 (23.3&#x02013;29.6)</td><td align="left">25.9 (4.7)</td><td align="left">25.5 (23.1&#x02013;28.0)</td><td char="." align="char">0.410</td></tr><tr><td align="left">APACHE II<sup>b</sup></td><td align="left">23.1 (8.1)</td><td align="left">23 (18&#x02013;29)</td><td align="left">26.2 (8.3)</td><td align="left">25 (20&#x02013;33)</td><td char="." align="char">0.036</td></tr><tr><td align="left">SOFA</td><td align="left">9.7 (3.8)</td><td align="left">11 (7&#x02013;12)</td><td align="left">10.8 (3.5)</td><td align="left">11 (8&#x02013;14)</td><td char="." align="char">0.071</td></tr><tr><td align="left">CURB-65<sup>c</sup></td><td align="left">2.7 (1.1)</td><td align="left">3 (2&#x02013;4)</td><td align="left">2.8 (1.3)</td><td align="left">3 (2&#x02013;4)</td><td char="." align="char">0.637</td></tr><tr><td align="left">PaO<sub>2</sub>/FiO<sub arrange="stack">2</sub><sup arrange="stack">d</sup></td><td align="left">134.7 (72.5)</td><td align="left">110.0 (82.0&#x02013;173.6)</td><td align="left">133.7 (72.5)</td><td align="left">106.5 (77.0&#x02013;185.7)</td><td char="." align="char">0.937</td></tr><tr><td align="left">IgM (g/L)</td><td align="left">0.8 (0.79)</td><td align="left">0.6 (0.4&#x02013;0.9)</td><td align="left">0.7 (0.41)</td><td align="left">0.6 (0.4&#x02013;0.9)</td><td char="." align="char">0.186</td></tr><tr><td align="left">IgG (g/L)</td><td align="left">6.8 (2.73)</td><td align="left">6.7 (5.0&#x02013;8.9)</td><td align="left">6.6 (3.04)</td><td align="left">6.4 (4.2&#x02013;8.2)</td><td char="." align="char">0.530</td></tr><tr><td align="left">IgA (g/L)</td><td align="left">2.3 (1.14)</td><td align="left">2.1 (1.4&#x02013;3.1)</td><td align="left">2.5 (1.78)</td><td align="left">2.0 (1.3&#x02013;3.2)</td><td char="." align="char">0.322</td></tr><tr><td align="left">CRP (mg/L)<sup>e</sup></td><td align="left">220 (130.8)</td><td align="left">217 (121.5&#x02013;325.3)</td><td align="left">227 (147.5)</td><td align="left">235 (88.2&#x02013;333.5)</td><td char="." align="char">0.723</td></tr><tr><td align="left">PCT (ng/mL)<sup>f</sup></td><td align="left">8.3 (12.9)</td><td align="left">2.3 (0.7&#x02013;10.4)</td><td align="left">23.3 (31.75)</td><td align="left">8.7 (1.9&#x02013;30.6)</td><td char="." align="char">0.0004</td></tr><tr><td align="left" colspan="6">Medical history, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Cardiac disorders<sup>g</sup></td><td align="left" colspan="2">39 (48.1)</td><td align="left" colspan="2">41 (51.9)</td><td char="." align="char">0.752</td></tr><tr><td align="left">&#x000a0;&#x000a0;Hypertension<sup>h</sup></td><td align="left" colspan="2">42 (51.9)</td><td align="left" colspan="2">42 (53.2)</td><td char="." align="char">0.876</td></tr><tr><td align="left">&#x000a0;&#x000a0;Diabetes mellitus<sup>h</sup></td><td align="left" colspan="2">15 (18.5)</td><td align="left" colspan="2">6 (7.6)</td><td char="." align="char">0.060</td></tr><tr><td align="left">&#x000a0;&#x000a0;Nervous system disorders<sup>g</sup></td><td align="left" colspan="2">21 (25.9)</td><td align="left" colspan="2">22 (27.8)</td><td char="." align="char">0.859</td></tr><tr><td align="left">&#x000a0;&#x000a0;Neoplasm (benign, malignant, and unspecified)<sup>g</sup></td><td align="left" colspan="2">22 (27.2)</td><td align="left" colspan="2">17 (21.5)</td><td char="." align="char">0.463</td></tr><tr><td align="left">&#x000a0;&#x000a0;Renal and urinary disorders<sup>g</sup></td><td align="left" colspan="2">41 (50.6)</td><td align="left" colspan="2">40 (50.6)</td><td char="." align="char">1.000</td></tr><tr><td align="left">&#x000a0;&#x000a0;Sepsis<sup>h</sup></td><td align="left" colspan="2">13 (16.0)</td><td align="left" colspan="2">10 (12.7)</td><td char="." align="char">0.654</td></tr><tr><td align="left">&#x000a0;&#x000a0;Septic shock<sup>h</sup></td><td align="left" colspan="2">35 (43.2)</td><td align="left" colspan="2">44 (55.7)</td><td char="." align="char">0.154</td></tr><tr><td align="left">&#x000a0;&#x000a0;Hepatic cirrhosis<sup>h</sup></td><td align="left" colspan="2">5 (6.2)</td><td align="left" colspan="2">0 (0.0)</td><td char="." align="char">0.059</td></tr><tr><td align="left" colspan="6">Medication at baseline, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Corticosteroids for systemic use</td><td align="left" colspan="2">24 (29.6)</td><td align="left" colspan="2">21 (26.6)</td><td char="." align="char">0.375</td></tr><tr><td align="left">&#x000a0;&#x000a0;Antivirals for systemic use</td><td align="left" colspan="2">11 (13.6)</td><td align="left" colspan="2">12 (15.2)</td><td char="." align="char">0.824</td></tr></tbody></table><table-wrap-foot><p>Data not available for <sup>a</sup>8 patients; <sup>b</sup>2 patients; <sup>c</sup>5 patients; <sup>d</sup>11 patients; <sup>e</sup>Baseline data substituted by day 1 data in 5 patients because of missing values. Data not available for 4 patients; <sup>f</sup>Baseline data substituted by day 1 data in 10 patients because of missing values. Data not available for 15 patients; <sup>g</sup>System Organ Class; <sup>h</sup>Preferred Term</p><p>Data are <italic>n</italic> (%), mean (SD), or median (IQR, 25th&#x02013;75th percentile)</p><p><italic>APACHE II</italic> Acute Physiology and Chronic Health Evaluation; <italic>BMI</italic> body mass index; <italic>CRP</italic> C-reactive protein; <italic>CURB</italic>-<italic>65</italic> Confusion, elevated blood Urea nitrogen, Respiratory rate, Blood pressure, 65&#x000a0;years of age and older; <italic>IgM, IgG, IgA</italic> immunoglobulin M, G, and A; <italic>IQR</italic> interquartile range; <italic>PaO</italic><sub><italic>2</italic></sub><italic>/FiO</italic><sub><italic>2</italic></sub> ratio of arterial oxygen partial pressure to fractional inspired oxygen; <italic>PCT</italic> procalcitonin; <italic>SD</italic> standard deviation; <italic>SOFA</italic> Sequential Organ Failure Assessment score</p><p>*<italic>p</italic> values were calculated post hoc by Chi-square test for sex, two-sided<italic> t&#x000a0;</italic>test for age, BMI, PaO<sub>2</sub>/FiO<sub>2</sub>, IgM/A/G, CRP, and PCT; by two-sided Wilcoxon rank sum test for APACHE II, SOFA, and CURB-65; or by Fisher exact test for all medical history outcomes and concomitant medication</p></table-wrap-foot></table-wrap>
</p><p id="Par27">About 50% of patients had positive diagnosis by means of microbiological testing (Supplementary Table&#x000a0;S1). The most frequent pathogens identified in both groups were species of <italic>Streptococci</italic> and <italic>Staphylococci</italic>, and approximately 20% of patients were diagnosed with viral pneumonia.</p><p id="Par28">Antibiotic treatment and use of systemic corticosteroids were comparable between the treatment groups (Supplementary Tables&#x000a0;S2 and S3). The majority of patients were treated according to the recommendations of the Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of CAP in adults and received antibiotic combination therapy (&#x003b2;-lactams&#x02009;+&#x02009;macrolides or &#x003b2;-lactams&#x02009;+&#x02009;fluoroquinolones). No significant differences in time to ICU admission were identified between treatment groups or study centers (data not shown).</p><p id="Par29">Overall, the difference in the mean number of VFDs (primary endpoint) between the trimodulin and placebo groups was 1.4&#x000a0;days in favor of trimodulin, which was not statistically significant (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Overview of primary and secondary efficacy endpoints in trimodulin and placebo treatment groups in all patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Endpoint</th><th align="left" colspan="2">Trimodulin</th><th align="left" colspan="2">Placebo</th><th align="left" rowspan="2"><italic>p</italic> value</th></tr><tr><th align="left">Mean (SD)</th><th align="left">Median (IQR)</th><th align="left">Mean (SD)</th><th align="left">Median (IQR)</th></tr></thead><tbody><tr><td align="left">VFDs</td><td align="left" colspan="2"><italic>n&#x02009;</italic>&#x000a0;=&#x02009;81</td><td align="left" colspan="2"><italic>n&#x02009;</italic>&#x000a0;=&#x02009;79</td><td align="left"/></tr><tr><td align="left"/><td align="left">11.0 (9.5)</td><td align="left">11.0 (0&#x02013;20)</td><td align="left">9.6 (9.4)</td><td align="left">8.0 (0&#x02013;19)</td><td align="left">0.173 *</td></tr><tr><td align="left">Duration of mechanical ventilation (days)<sup>a</sup></td><td align="left" colspan="2"><italic>n&#x02009;</italic>&#x000a0;=&#x02009;81</td><td align="left" colspan="2"><italic>n&#x02009;</italic>&#x000a0;=&#x02009;79</td><td align="left"/></tr><tr><td align="left"/><td align="left">12.8 (8.5)</td><td align="left">10.0 (6&#x02013;19)</td><td align="left">13.8 (8.6)</td><td align="left">11.0 (7&#x02013;21)</td><td align="left">Not calculated</td></tr><tr><td align="left">VFDs in surviving patients</td><td align="left" colspan="2"><italic>n&#x02009;</italic>&#x000a0;=&#x02009;63</td><td align="left" colspan="2"><italic>n&#x02009;</italic>&#x000a0;=&#x02009;57</td><td align="left"/></tr><tr><td align="left"/><td align="left">14.2 (8.4)</td><td align="left">18.0 (8&#x02013;21)</td><td align="left">13.3 (8.5)</td><td align="left">16.0 (4&#x02013;20)</td><td align="left">0.271<sup>&#x02020;</sup></td></tr><tr><td align="left">Vasopressor-free days</td><td align="left" colspan="2"><italic>n&#x02009;</italic>&#x000a0;=&#x02009;81</td><td align="left" colspan="2"><italic>n&#x02009;</italic>&#x000a0;=&#x02009;79</td><td align="left"/></tr><tr><td align="left"/><td align="left">13.0 (8.9)</td><td align="left">14.0 (6&#x02013;20)</td><td align="left">13.7 (8.4)</td><td align="left">15.0 (8&#x02013;20)</td><td align="left">0.639<sup>&#x02020;</sup></td></tr><tr><td align="left">Discharge time from ICU (days)</td><td align="left" colspan="2"><italic>n&#x02009;</italic>&#x000a0;=&#x02009;81<sup>b</sup></td><td align="left" colspan="2"><italic>n&#x02009;</italic>&#x000a0;=&#x02009;79<sup>b</sup></td><td align="left"/></tr><tr><td align="left"/><td align="left">13.4 (5.9)</td><td align="left">11.0 (9&#x02013;17)</td><td align="left">14.4 (5.8)</td><td align="left">13.0 (10&#x02013;18)</td><td align="left">0.161<sup>&#x02020;</sup></td></tr><tr><td align="left">Discharge time from hospital (days)</td><td align="left" colspan="2"><italic>n&#x02009;</italic>&#x000a0;=&#x02009;81</td><td align="left" colspan="2"><italic>n&#x02009;</italic>&#x000a0;=&#x02009;79</td><td align="left"/></tr><tr><td align="left"/><td align="left">19.5 (5.5)</td><td align="left">20.0 (15&#x02013;24)</td><td align="left">19.0 (4.9)</td><td align="left">19.0 (15&#x02013;23)</td><td align="left">0.479</td></tr><tr><td align="left">28-day all-cause mortality, <italic>n</italic> (%)</td><td align="left" colspan="2">18/81 (22.2)</td><td align="left" colspan="2">22/79 (27.8)</td><td align="left">0.465<sup>&#x02021;</sup></td></tr><tr><td align="left">28-day pneumonia-related mortality, <italic>n</italic> (%)</td><td align="left" colspan="2">5/81 (6.2)</td><td align="left" colspan="2">10/79 (12.7)</td><td align="left">Not calculated</td></tr><tr><td align="left">Change in SOFA score from day 1 to 7</td><td align="left">&#x02212;4.8 (7.5)</td><td align="left">&#x02212;7.0 (&#x02212;10&#x02013;0)</td><td align="left">&#x02212;5.4 (6.5)</td><td align="left">&#x02212;7.0 (&#x02212;10 to 3.0)</td><td align="left">Not calculated</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Mortality is not considered for duration of mechanical ventilation; <sup>b</sup>34 patients were missing in the trimodulin group and 38 in the placebo group</p><p><italic>ICU</italic> intensive care unit, <italic>IQR</italic> interquartile range, <italic>SD</italic> standard deviation, <italic>SOFA</italic> Sequential Organ Failure Assessment, <italic>VFD</italic> ventilator-free day</p><p>Data are <italic>n</italic> (%), mean (SD) and median (IQR, 25th&#x02013;75th percentile)</p><p>*One-sided Wilcoxon&#x02013;Mann&#x02013;Whitney test; <sup>&#x02020;</sup>Wilcoxon test; <sup>&#x02021;</sup>Mantel&#x02013;Haenszel test</p></table-wrap-foot></table-wrap>
</p><p id="Par30">There was an absolute reduction in 28-day all-cause mortality of 5.6% (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) and a relative reduction in mortality of 20.1% in the trimodulin group versus placebo. For pneumonia-related mortality, the absolute reduction was 6.5% (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) and the relative reduction was 51.2%. Time to discharge from ICU to the ward, mean duration of hospitalization, and vasopressor-free days were not significantly different (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Survival by treatment regimen</p></caption><graphic xlink:href="134_2018_5143_Fig2_HTML" id="MO2"/></fig>
</p><p id="Par31">TEAE incidences (including serious AEs [SAEs]), overall and throughout the majority of System Organ Classes (SOCs), were comparable between the trimodulin and placebo groups. Differences considered relevant for the trimodulin group were observed in the SOCs &#x0201c;renal and urinary disorders&#x0201d; and &#x0201c;hepatobiliary disorders&#x0201d;; these mainly resulted from &#x0201c;acute renal failure&#x0201d; (reported in 17 [21%] individuals in the trimodulin group and 8 [10.1%] in the placebo group) and &#x0201c;cholestasis&#x0201d; (reported by 8 [9.9%] and 2 [2.5%] individuals in the trimodulin and placebo groups, respectively). There were significantly more TEAEs in the SOC &#x0201c;infections and infestations&#x0201d; reported in the placebo group (<italic>p</italic>&#x02009;=&#x02009;0.004; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Overview of treatment-emergent adverse events (TEAEs; safety analysis set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Trimodulin (<italic>n</italic>&#x02009;=&#x02009;81)</th><th align="left">Placebo (<italic>n</italic>&#x02009;=&#x02009;79)</th><th align="left"><italic>p</italic> value*</th></tr></thead><tbody><tr><td align="left">Overall incidence</td><td char="(" align="char">75 (92.6)</td><td char="(" align="char">75 (94.9)</td><td char="." align="char">0.746</td></tr><tr><td align="left">TEAEs with onset during infusion and up to 24&#x000a0;h after infusion end</td><td char="(" align="char">67 (82.7)</td><td char="(" align="char">67 (84.8)</td><td char="." align="char">0.831</td></tr><tr><td align="left">Serious TEAEs</td><td char="(" align="char">62 (76.5)</td><td char="(" align="char">62 (78.5)</td><td char="." align="char">0.850</td></tr><tr><td align="left">TEAEs with fatal outcome<sup>a</sup></td><td char="(" align="char">20 (24.7)</td><td char="(" align="char">23 (29.1)</td><td char="." align="char">0.594</td></tr><tr><td align="left">Discontinuation due to TEAEs</td><td char="(" align="char">2 (2.5)</td><td char="(" align="char">1 (1.3)</td><td char="." align="char">1.000</td></tr><tr><td align="left" colspan="4">TEAEs by System Organ Class (&#x02265;&#x02009;5% of patients)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Blood and lymphatic system disorders</td><td char="(" align="char">33 (40.7)</td><td char="(" align="char">34 (43.0)</td><td char="." align="char">0.873</td></tr><tr><td align="left">&#x000a0;&#x000a0;Cardiac disorders</td><td char="(" align="char">31 (38.3)</td><td char="(" align="char">27 (34.2)</td><td char="." align="char">0.624</td></tr><tr><td align="left">&#x000a0;&#x000a0;Vascular disorders</td><td char="(" align="char">30 (37.0)</td><td char="(" align="char">30 (38.0)</td><td char="." align="char">1.000</td></tr><tr><td align="left">&#x000a0;&#x000a0;Metabolism and nutrition disorders</td><td char="(" align="char">29 (35.8)</td><td char="(" align="char">29 (36.7)</td><td char="." align="char">1.000</td></tr><tr><td align="left">&#x000a0;&#x000a0;Respiratory, thoracic, and mediastinal disorders</td><td char="(" align="char">29 (35.8)</td><td char="(" align="char">40 (50.6)</td><td char="." align="char">0.079</td></tr><tr><td align="left">&#x000a0;&#x000a0;Gastrointestinal disorders</td><td char="(" align="char">27 (33.3)</td><td char="(" align="char">36 (45.6)</td><td char="." align="char">0.145</td></tr><tr><td align="left">&#x000a0;&#x000a0;Infections and infestations</td><td char="(" align="char">27 (33.3)</td><td char="(" align="char">45 (57.0)</td><td char="." align="char">0.004</td></tr><tr><td align="left">&#x000a0;&#x000a0;General disorders and administration-site conditions</td><td char="(" align="char">22 (27.2)</td><td char="(" align="char">31 (39.2)</td><td char="." align="char">0.131</td></tr><tr><td align="left">&#x000a0;&#x000a0;Renal and urinary disorders</td><td char="(" align="char">20 (24.7)</td><td char="(" align="char">12 (15.2)</td><td char="." align="char">0.167</td></tr><tr><td align="left">&#x000a0;&#x000a0;Psychiatric disorders</td><td char="(" align="char">18 (22.2)</td><td char="(" align="char">23 (29.1)</td><td char="." align="char">0.367</td></tr><tr><td align="left">&#x000a0;&#x000a0;Investigations</td><td char="(" align="char">15 (18.5)</td><td char="(" align="char">13 (16.5)</td><td char="." align="char">0.836</td></tr><tr><td align="left">&#x000a0;&#x000a0;Skin and subcutaneous tissue disorders</td><td char="(" align="char">14 (17.3)</td><td char="(" align="char">14 (17.7)</td><td char="." align="char">1.000</td></tr><tr><td align="left">&#x000a0;&#x000a0;Nervous system disorders<sup>b</sup></td><td char="(" align="char">13 (16.0)</td><td char="(" align="char">8 (10.1)</td><td char="." align="char">0.350</td></tr><tr><td align="left">&#x000a0;&#x000a0;Hepatobiliary disorders</td><td char="(" align="char">12 (14.8)</td><td char="(" align="char">4 (5.1)</td><td char="." align="char">0.063</td></tr><tr><td align="left">&#x000a0;&#x000a0;Musculoskeletal and connective tissue disorders</td><td char="(" align="char">9 (11.1)</td><td char="(" align="char">11 (13.9)</td><td char="." align="char">0.639</td></tr><tr><td align="left">&#x000a0;&#x000a0;Injury, poisoning, and connective tissue disorders</td><td char="(" align="char">8 (9.9)</td><td char="(" align="char">8 (10.1)</td><td char="." align="char">1.000</td></tr></tbody></table><table-wrap-foot><p>Data are <italic>n</italic> (%)</p><p>There were no adverse drug reactions leading to death in either treatment group</p><p><sup>a</sup>Safety set includes patients with TEAE onset before day 28, but who died due to TEAE after day 28</p><p><sup>b</sup>All events were reported for single patients only, except for critical illness polyneuropathy and vocal cord paralysis, each reported for 2 (2.5%) patients in the trimodulin group, and headache, which was reported for 3 (3.7%) patients in the trimodulin group</p><p>*<italic>p</italic> values were calculated post hoc by Fisher exact test</p></table-wrap-foot></table-wrap>
</p><p id="Par32">Exploratory post hoc analyses were performed to identify patient subsets that may benefit most from trimodulin treatment (Supplementary Figs.&#x000a0;S1 and S2). Cutoff values were set to values with maximum mortality difference between the treatment groups. Only groups representing the majority of the study population are reported here. The post hoc subsets presented included 124 (77.5%) patients with baseline levels of high CRP, 111 (69.4%) patients with low IgM, 92 (57.5%) patients with combined high CRP and low IgM, and 94 (58.8%) patients with high PCT.</p><p id="Par33">In general, no significant differences in patient demographics and other baseline characteristics were identified between the patient subsets of the treatment groups (Supplementary Tables&#x000a0;S4&#x02013;7) with the following exceptions: lower SOFA scores and PCT values in the trimodulin group (CRP and PCT subsets), lower APACHE II scores and PCT levels in the trimodulin group (IgM subset), and lower levels of PCT in the trimodulin group (CRP/IgM subset). Adjustment for the difference in PCT values was performed by exclusion of PCT outliers. The remaining patients had comparable PCT values and still showed substantial mortality difference between the treatment arms. In summary, the difference in PCT values does not explain the observed mortality difference in the subsets.</p><p id="Par34">The differences in mean VFDs for trimodulin versus placebo were 2.9, 3.5, 3.9, and 3.4&#x000a0;days in the high CRP, low IgM, combined high CRP/low IgM, and high PCT subsets, respectively (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Importantly, 28-day all-cause mortality was substantially reduced in the trimodulin group versus placebo in each subset (absolute reductions of 16.7%, 16.6%, 24.8%, and 8.1%, respectively), with a reduction in absolute mortality of up to 24.8% (<italic>p</italic>&#x02009;=&#x02009;0.006) in the combined high CRP/low IgM subset (68.0% relative reduction; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Kaplan&#x02013;Meier analyses for the high CRP, low IgM, and combined subsets are presented in Supplementary Figs.&#x000a0;S3&#x02013;5. Data on 28-day all-cause mortality for all patient groups analyzed, including those that did not represent the majority of the study population, are reported in Supplementary Table&#x000a0;S8.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>VFDs in trimodulin and placebo groups in patient subsets</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Patient subset</th><th align="left">Trimodulin</th><th align="left">Placebo</th><th align="left" rowspan="2"><italic>p</italic> value*</th></tr><tr><th align="left">VFD mean (95% CI)</th><th align="left">VFD mean (95% CI)</th></tr></thead><tbody><tr><td align="left" rowspan="2">CRP&#x02009;&#x02265;&#x02009;70&#x000a0;mg/L</td><td align="left"><italic>n&#x02009;</italic>=&#x02009;65</td><td align="left"><italic>n&#x02009;</italic>=&#x02009;59</td><td align="left"/></tr><tr><td align="left">12.1 (9.8&#x02013;14.4)</td><td align="left">9.2 (6.8&#x02013;11.6)</td><td align="left">0.044</td></tr><tr><td align="left" rowspan="2">IgM&#x02009;&#x02264;&#x02009;0.8&#x000a0;g/L</td><td align="left"><italic>n&#x02009;</italic>=&#x02009;56</td><td align="left"><italic>n&#x02009;</italic>=&#x02009;55</td><td align="left"/></tr><tr><td align="left">12.4 (10.0&#x02013;14.9)</td><td align="left">8.9 (6.5&#x02013;11.4)</td><td align="left">0.031</td></tr><tr><td align="left" rowspan="2">CRP&#x02009;&#x02265;&#x02009;70&#x000a0;mg/L and IgM&#x02009;&#x02264;&#x02009;0.8&#x000a0;g/L</td><td align="left"><italic>n&#x02009;</italic>=&#x02009;51</td><td align="left"><italic>n&#x02009;</italic>=&#x02009;41</td><td align="left"/></tr><tr><td align="left">12.6 (10.1&#x02013;15.2)</td><td align="left">8.7 (5.8&#x02013;11.6)</td><td align="left">0.031</td></tr><tr><td align="left" rowspan="2">PCT&#x02009;&#x02265;&#x02009;2&#x000a0;ng/mL</td><td align="left"><italic>n&#x02009;</italic>=&#x02009;43</td><td align="left"><italic>n&#x02009;</italic>=&#x02009;51</td><td align="left"/></tr><tr><td align="left">11.2 (8.2&#x02013;14.1)</td><td align="left">7.8 (5.2&#x02013;10.3)</td><td align="left">0.047</td></tr></tbody></table><table-wrap-foot><p>Data are mean&#x02009;&#x000b1;&#x02009;95% confidence interval (CI)</p><p>CRP, IgM, and PCT were measured at baseline</p><p><italic>CI</italic> confidence interval, <italic>CRP</italic> C-reactive protein, <italic>IgM</italic> immunoglobulin&#x000a0;M, <italic>PCT</italic> procalcitonin, <italic>VFD</italic> ventilator-free day</p><p>*One-sided <italic>p</italic> values based on Wilcoxon rank sum test with continuity correction (0.5); significance level 0.025</p></table-wrap-foot></table-wrap>
<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Twenty-eight-day all-cause mortality in trimodulin and placebo treatment groups in all patients and in patient subsets. Mortality was assessed in all patients and in stratified patient populations based on baseline levels of C-reactive protein (CRP)&#x02009;&#x02265;&#x02009;70&#x000a0;mg/L, immunoglobulin (Ig) M&#x02009;&#x02264;&#x02009;0.8&#x000a0;g/L, or both criteria combined, or procalcitonin (PCT)&#x02009;&#x02265;&#x02009;2.0&#x000a0;ng/mL. Actual numbers of deaths are given at the bottom of each column</p></caption><graphic xlink:href="134_2018_5143_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><p id="Par35">The CIGMA study was designed to evaluate the efficacy and safety of a novel therapeutic polyclonal antibody preparation, trimodulin, in severely ill patients with sCAP.</p><p id="Par36">Although the difference observed in the primary endpoint of VFDs, with a mean increase of 1.4 days and median increase of 3&#x000a0;days in favor of trimodulin, was not significant, this difference may be considered clinically relevant. According to the clinical study protocol, the study was powered to detect a mean difference of 2&#x000a0;days between treatment groups. Further, although the study was not powered for mortality, and the reductions in 28-day all-cause and pneumonia-related mortality were not significant with add-on trimodulin compared with placebo, the relative reductions of 20% in all-cause mortality and 51% in pneumonia-related mortality in trimodulin-treated patients warrant further investigation.</p><p id="Par37">In the CIGMA study, IgM levels were low in the majority of patients compared with the normal range. IgM levels range from 0.4 to 2.5&#x000a0;g/L [<xref ref-type="bibr" rid="CR24">24</xref>]. Historical data suggest that low IgA and IgG levels are associated with a greater risk of mortality in CAP [<xref ref-type="bibr" rid="CR25">25</xref>], and that low IgM concentrations in patients with sepsis or viral infections are related to a negative outcome [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par38">Moreover, high CRP and PCT levels may be prognostic of poor outcomes in CAP [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. In our subgroup analysis, the cutoffs for levels of CRP (&#x02265;&#x02009;70&#x000a0;mg/L) and PCT (&#x0003e;&#x02009;2&#x000a0;ng/mL) are comparable to historically published values, and high levels of each may generally be considered to indicate systemic and severe infections [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Torres et al. showed that methylprednisolone reduced treatment failure compared with placebo in 120 patients with sCAP and a high systemic inflammatory response (CRP&#x02009;&#x0003e;&#x02009;150&#x000a0;mg/L); in-hospital mortality, however, was similar [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par39">In the post hoc analyses of the CIGMA study reported here, absolute mortality reduction was 16.7% for the high CRP subset, 16.6% for the low IgM subset, and 24.8% for the combined high CRP/low IgM subset; the relative reduction in mortality was 54&#x02013;68% in favor of trimodulin.</p><p id="Par40">The definition of pneumonia-related death or comorbidity was challenging in this complex patient population and required a subjective assessment of each case by the investigator. Further, comorbidities at study entry may particularly influence outcome in elderly patients&#x02014;the relatively high all-cause mortality in trimodulin-treated patients &#x0003e;&#x02009;65&#x000a0;years of age compared with patients 40&#x02013;65&#x000a0;years of age may be associated with comorbidities rather than with an underlying infection (data not shown). Indeed, many patients who died did not have elevated CRP (data not shown). Generally, diagnosis of CAP is complex and may result in misdiagnosis, and inflammation parameters, such as CRP, have been investigated to support diagnosis [<xref ref-type="bibr" rid="CR31">31</xref>]. In a future clinical trial with trimodulin in sCAP, CRP could help to support the diagnosis and differentiate sCAP from other conditions (by excluding patients with similar symptoms who have other underlying diseases), thereby enrolling a more targeted study population.</p><p id="Par41">In the present study, incidences of TEAEs (including SAEs) were comparable between both treatment groups. Most patients had multiple comorbidities. SOCs with TEAEs reported more frequently in the trimodulin group were &#x0201c;renal and urinary disorders&#x0201d; and &#x0201c;hepatobiliary disorders&#x0201d; mainly resulting from patients experiencing &#x0201c;acute renal failure&#x0201d; (21% patients in the trimodulin group vs. 10.1% in the placebo group) and non-serious &#x0201c;cholestasis&#x0201d; (9.9% vs. 2.5%, respectively). Acute renal failure is a common comorbidity in sCAP [<xref ref-type="bibr" rid="CR3">3</xref>], and is an established potential risk during conventional intravenous IgG treatment [<xref ref-type="bibr" rid="CR32">32</xref>]. All cases of acute renal failure in the current study occurred in patients with pre-existing renal impairment and in patients at high risk for renal failure. Notably, the incidence of renal TEAEs in the trimodulin group (21%) was lower than would be expected in patients with sCAP, in whom the incidence of acute kidney injury has been reported to be up to 38% (10/26) [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par42">Confounding factors were identified in all patients with cholestasis, including parallel intake/infusion of multiple drugs with possible effects on the liver, and/or confounding medical history. All adverse drug reactions of cholestasis were reported from one study center, so the possibility of a treatment interaction with concomitant medication should be considered.</p><p id="Par43">Targeting the immune response with novel therapies such as trimodulin may provide additional protection against secondary infections and reduce mortality due to infection-related TEAEs such as sepsis. In this study, the incidence of TEAEs of all types of infection was significantly lower with trimodulin add-on treatment than with placebo, suggesting an additional protective effect against infection.</p><p id="Par44">All of the above TEAEs are considered to be controllable under ICU conditions and close monitoring. Despite the failed primary endpoint, but given the trend in reduction of mortality further solidified by post hoc analyses, the risk profile of trimodulin is considered favorable for further clinical investigations.</p><p id="Par45">Limitations of this study were that biomarkers and cutoff values used in the post hoc analyses were not prespecified in the study protocol. In addition, for the stratification of the patients into subsets, only baseline PCT values were used: data from serial measurements were not considered. There was a significant difference in baseline PCT values, with higher mean values in the placebo group. Further statistical tests were performed to adjust for this difference (data not shown). However, the difference in baseline PCT values does not explain the observed mortality differences between the treatment arms in the patient subsets. In future clinical trials with trimodulin, serial PCT measurements will be considered, as lack of reduction in PCT levels may better predict treatment failure and mortality than absolute values. Additionally, differences in severity of illness (APACHE II and SOFA score) were observed in this study in favor of the control group. However, these differences were not significant in the high CRP/low IgM subset, which showed the highest survival benefit for trimodulin. Finally, although patients received antibiotics on the day of randomization, the exact time point of treatment initiation was not recorded.</p></sec><sec id="Sec9" sec-type="conclusion"><title>Conclusions</title><p id="Par46">The phase II CIGMA study reported here did not meet the primary endpoint of VFDs following add-on treatment with trimodulin in severely ill patients with sCAP. However, post hoc analyses of patient subsets with high CRP, low IgM, and combined high CRP/low IgM baseline levels could be used to inform further investigation of trimodulin in a large, global phase III study that is powered for mortality in a targeted patient population with sCAP.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec10"><p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="134_2018_5143_MOESM1_ESM.docx"><caption><p>Supplementary material 1 (DOCX 289 kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (10.1007/s00134-018-5143-7) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><p>Professional medical writing assistance was provided by Fiona Boswell, PhD, and editorial assistance was provided by Katie Lay, MSc, at Caudex (Oxford, UK), funded by Biotest AG. Accovion GmbH, Eschborn, Germany (now Clinipace Worldwide, Morrisville, North Carolina, USA) provided study management services. We would like to thank all centers and staff involved in this study, and the patients and their families. Bernd H. Belohradsky, V. Marco Ranieri (Chair), Richard Strauss, and Gerhard W. Sybrecht monitored patient safety and data integrity as members of the DSMB.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>All authors critically reviewed drafts of the manuscript, had final approval of the version to be published, attest to the accuracy and integrity of the data, and agree to be accountable for all respective aspects of the work. TW contributed to study conception and design, patient recruitment, acquisition of data, and data analysis and interpretation. RPD contributed to study conception and design, and data analysis and interpretation. HE contributed to study conception and design, patient recruitment, acquisition of data, and data analysis and interpretation. MF contributed to study conception and design, patient recruitment, and data analysis and interpretation. SMO contributed to study conception and design, data analysis and interpretation, attests to the accuracy of the study report, and agrees to be accountable for its contents. MS contributed to data analysis and interpretation. J-LV contributed to study conception and design, patient recruitment, acquisition of data, and data analysis and interpretation. KW contributed to study conception and design, patient recruitment, and data analysis and interpretation. IM-L contributed to patient recruitment, acquisition of data, and data analysis and interpretation. JA contributed to patient recruitment, acquisition of data, and data analysis and interpretation. AA contributed to patient recruitment, acquisition of data, and data analysis and interpretation. JIA contributed to patient recruitment, acquisition of data, and data analysis and interpretation. SN contributed to patient recruitment, acquisition of data, and data analysis and interpretation. RF contributed to patient recruitment, acquisition of data, and data analysis and interpretation. GSR contributed to patient recruitment, acquisition of data, and data analysis and interpretation. MS-H contributed to patient recruitment, acquisition of data, and data analysis and interpretation. FA-L contributed to patient recruitment, acquisition of data, and data analysis and interpretation. RR contributed to patient recruitment, acquisition of data, and data analysis and interpretation. J-MS contributed to study conception and design, patient recruitment, acquisition of data, and data analysis and interpretation. SK contributed to patient recruitment, acquisition of data, and data analysis and interpretation. KZ contributed to patient recruitment, acquisition of data, and data analysis and interpretation. JBM contributed to patient recruitment and acquisition of data. HL contributed to patient recruitment, acquisition of data, and data analysis and interpretation. GW contributed to study conception and design, patient recruitment, acquisition of data, and data analysis and interpretation. UA contributed to study conception and design, patient recruitment, and acquisition of data. DB contributed to patient recruitment, acquisition of data, and data analysis and interpretation. AK contributed to patient recruitment, acquisition of data, and data analysis and interpretation. MSG contributed to patient recruitment, acquisition of data, and data analysis and interpretation. JB contributed to patient recruitment and acquisition of data. MK contributed to patient recruitment and data analysis and interpretation. HPR contributed to patient recruitment, acquisition of data, and data analysis and interpretation. MPW contributed to patient recruitment, acquisition of data, and data analysis and interpretation. BHB contributed to data analysis and interpretation. IB contributed to study conception and design, patient recruitment, and acquisition of data. BD contributed to data analysis and interpretation. PD contributed to data analysis and interpretation. PL contributed to study conception and design, patient recruitment, acquisition of data, and data analysis and interpretation. MM contributed to acquisition of data and data analysis and interpretation. JS contributed to data analysis and interpretation. AW-D contributed to study conception and design, and data analysis and interpretation. UW contributed to study conception and design, and data analysis and interpretation. DW contributed to study conception and design, and data analysis and interpretation. AT contributed to study conception and design, patient recruitment, acquisition of data, and data analysis and interpretation.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was sponsored by Biotest AG, Dreieich, Germany. Biotest employees and contract research organization subcontractors were involved in the study design, data collection, analysis and interpretation, and writing of this manuscript.</p></notes><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar2"><title>Conflicts of interests</title><p id="Par47">TW has served on advisory boards, received funding for institutional research, and honoraria from Biotest AG. RPD has received personal fees from Biotest AG for serving on the advisory board for this trial, institutional funding from Spectral Diagnostics, and personal fees for consulting from Merck, Bristol-Myers Squibb, and Spectral. HE has served on advisory boards for Biotest AG and received honoraria from Biotest AG. MF has served on advisory boards for Biotest AG. SMO has served on advisory boards for Aridis and Arsanis, and received institutional funding from Asahi Kasei and Ferring, and consultancy fees from Biotest AG. MS has received honoraria from Biotest AG for participation in advisory boards and satellite symposia. KW is a member of the Biotest BT086 Advisory Board and has received honoraria, research funding, consulting fees, and funding for travel from Biotest AG. IM-L has served on advisory boards for Biotest AG. AA has received institutional research funding and honoraria from GRIFOLS Co, and consulting fees from Asahi Kasei. RF has received honoraria from MSD, Pfizer, and Toray. MS-H has received travel costs for speaking at a Biotest seminar. FA-L has served on advisory boards for Gilead and MSD. SK has served on advisory boards for ANOMED, Astellas, Baxter, Fresenius, Gambro, Gilead, MSD, NovaLung, Novartis, and Pfizer; has received institutional research funding from NovaLung and Pfizer, and honoraria from ArjoHuntleigh, Astellas, Basilea, Baxter, Biotest AG, CSL Behring, Cytosorbents, Fresenius, Gilead, MSD, NovaLung, Pfizer, Orion, Sedana, Sorin, and Thermo Fisher Scientific. KZ has received research grants, honoraria, and financial support (education) for his department from Abbott, AbbVie Deutschland KG, Aesculap Akademie, AIT GmbH, Amomed GmbH, art tempi GmbH, Ashai Kasai Pharma, Astellas Pharma, B. Braun Avitum AG, B. Braun Melsungen AG, Bayer AG, Biotest AG, Codan PVB Medical, Covidien GmbH, CSL Behring, Delab GmbH, Dr. F. K&#x000f6;hler Chemie, Dr Rothenberger, Dr&#x000e4;ger Medical, ECCPS, Edward Life Science GmbH, Enterprise Analyses, Envico SRL, European Union, Ferring Arzneimittel, Forum Sanitas, Fresenius Kabi, Fresenius Medical Care, German Research Federation Gilead, Haemonetics Corporation, Hamilton Medical AG, Heinen&#x02009;+&#x02009;L&#x000f6;wenstein, Hepanet GmbH, Hexal AG, High Tech Grundungsford, INC Research, Josef Gassner, Karl Storz AG, Kentours Producciones, LOEWE TP 6, M&#x00026;M Gesundheitsnetzwerk, Maquet GmbH, Marien-Akademie, Markus Lucke Kongress Organisation, Masimo, Massimo International, med-Update GmbH, Medtronic GmbH, MSD Sharp &#x00026; Dohme, Mundipharma GmbH, Nordic Group, Novartis Pharma GmbH, Novo Nordisk Pharma GmbH, Orion Pharma GmbH, Pall GmbH, Pfizer, Photonics GmbH, Pulsion Medical Systems S.E., Radiometer GmbH, Ratiopharm GmbH, Reha Medi GmbH, Salvia Medical GmbH, Sarstedt GmbH, Schochl Medical Research &#x000d6;sterreich, Serumwerke Berneburg, Siemens Healthcare, Smith Medical GmbH, Sorin Group, Sysmex, Teflex Medical GmbH, TEM International, Teva GmbH, Thieme Verlag, Verathon Medical, and Vifor Pharma. UA has received reimbursement for educational support and travel costs from Biotest AG. DB has received funding for institutional research at the trial site only. MK has served on advisory boards for MSD and Pfizer, and has received honoraria from Astellas, Gilead, MSD, and Pfizer. AT has served on advisory boards for Aridis, Bayer, GSK, Pfizer, Polyphor, and Roche. J-LV, JA, JIA, SN, GSR, RR, J-MS, JBM, HL, GW, AK, MSG, JB, HPR, MPW, and BHB have no interests to declare. IB, BD, PD, PL, MM, JS, AW-D, UW, and DW are employees of Biotest AG. UW, JS, and AW-D also hold stocks/shares in Biotest AG.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Peetermans</surname><given-names>WE</given-names></name><name><surname>Viegi</surname><given-names>G</given-names></name><name><surname>Blasi</surname><given-names>F</given-names></name></person-group><article-title>Risk factors for community-acquired pneumonia in adults in Europe: a literature review</article-title><source>Thorax</source><year>2013</year><volume>68</volume><fpage>1057</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2013-204282</pub-id><pub-id pub-id-type="pmid">24130229</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Self</surname><given-names>WH</given-names></name><name><surname>Wunderink</surname><given-names>RG</given-names></name><name><surname>Fakhran</surname><given-names>S</given-names></name><name><surname>Balk</surname><given-names>R</given-names></name><name><surname>Bramley</surname><given-names>AM</given-names></name><name><surname>Reed</surname><given-names>C</given-names></name><name><surname>Grijalva</surname><given-names>CG</given-names></name><name><surname>Anderson</surname><given-names>EJ</given-names></name><name><surname>Courtney</surname><given-names>DM</given-names></name><name><surname>Chappell</surname><given-names>JD</given-names></name><name><surname>Qi</surname><given-names>C</given-names></name><name><surname>Hart</surname><given-names>EM</given-names></name><name><surname>Carroll</surname><given-names>F</given-names></name><name><surname>Trabue</surname><given-names>C</given-names></name><name><surname>Donnelly</surname><given-names>HK</given-names></name><name><surname>Williams</surname><given-names>DJ</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Arnold</surname><given-names>SR</given-names></name><name><surname>Ampofo</surname><given-names>K</given-names></name><name><surname>Waterer</surname><given-names>GW</given-names></name><name><surname>Levine</surname><given-names>M</given-names></name><name><surname>Lindstrom</surname><given-names>S</given-names></name><name><surname>Winchell</surname><given-names>JM</given-names></name><name><surname>Katz</surname><given-names>JM</given-names></name><name><surname>Erdman</surname><given-names>D</given-names></name><name><surname>Schneider</surname><given-names>E</given-names></name><name><surname>Hicks</surname><given-names>LA</given-names></name><name><surname>McCullers</surname><given-names>JA</given-names></name><name><surname>Pavia</surname><given-names>AT</given-names></name><name><surname>Edwards</surname><given-names>KM</given-names></name><name><surname>Finelli</surname><given-names>L</given-names></name></person-group><article-title>Community-acquired pneumonia requiring hospitalization among U.S. adults</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>415</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1500245</pub-id><pub-id pub-id-type="pmid">26172429</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodhead</surname><given-names>M</given-names></name><name><surname>Welch</surname><given-names>CA</given-names></name><name><surname>Harrison</surname><given-names>DA</given-names></name><name><surname>Bellingan</surname><given-names>G</given-names></name><name><surname>Ayres</surname><given-names>JG</given-names></name></person-group><article-title>Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database</article-title><source>Crit Care</source><year>2006</year><volume>10</volume><issue>Suppl 2</issue><fpage>S1</fpage><pub-id pub-id-type="doi">10.1186/cc4927</pub-id><pub-id pub-id-type="pmid">16934135</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Fink</surname><given-names>MP</given-names></name><name><surname>Weissfeld</surname><given-names>LA</given-names></name><name><surname>Yealy</surname><given-names>DM</given-names></name><name><surname>Pinsky</surname><given-names>MR</given-names></name><name><surname>Fine</surname><given-names>J</given-names></name><name><surname>Krichevsky</surname><given-names>A</given-names></name><name><surname>Delude</surname><given-names>RL</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name></person-group><article-title>Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) study</article-title><source>Arch Intern Med</source><year>2007</year><volume>167</volume><fpage>1655</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.1001/archinte.167.15.1655</pub-id><pub-id pub-id-type="pmid">17698689</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calfee</surname><given-names>CS</given-names></name><name><surname>Delucchi</surname><given-names>K</given-names></name><name><surname>Parsons</surname><given-names>PE</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group><article-title>Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials</article-title><source>Lancet Respir Med</source><year>2014</year><volume>2</volume><fpage>611</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(14)70097-9</pub-id><pub-id pub-id-type="pmid">24853585</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alejandria</surname><given-names>MM</given-names></name><name><surname>Lansang</surname><given-names>MA</given-names></name><name><surname>Dans</surname><given-names>LF</given-names></name><name><surname>Mantaring</surname><given-names>JB</given-names><suffix>III</suffix></name></person-group><article-title>Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock</article-title><source>Cochrane Database Syst Rev</source><year>2013</year><pub-id pub-id-type="pmid">24043371</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreymann</surname><given-names>KG</given-names></name><name><surname>de Heer</surname><given-names>G</given-names></name><name><surname>Nierhaus</surname><given-names>A</given-names></name><name><surname>Kluge</surname><given-names>S</given-names></name></person-group><article-title>Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><fpage>2677</fpage><lpage>2685</lpage><pub-id pub-id-type="pmid">18074464</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sibila</surname><given-names>O</given-names></name><name><surname>Rodrigo-Troyano</surname><given-names>A</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name></person-group><article-title>Nonantibiotic adjunctive therapies for community-acquired pneumonia (corticosteroids and beyond): where are we with them?</article-title><source>Semin Respir Crit Care Med</source><year>2016</year><volume>37</volume><fpage>913</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1055/s-0036-1593538</pub-id><pub-id pub-id-type="pmid">27960215</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Sibila</surname><given-names>O</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Polverino</surname><given-names>E</given-names></name><name><surname>Menendez</surname><given-names>R</given-names></name><name><surname>Mensa</surname><given-names>J</given-names></name><name><surname>Gabarrus</surname><given-names>A</given-names></name><name><surname>Sellares</surname><given-names>J</given-names></name><name><surname>Restrepo</surname><given-names>MI</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Niederman</surname><given-names>MS</given-names></name><name><surname>Agusti</surname><given-names>C</given-names></name></person-group><article-title>Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial</article-title><source>JAMA</source><year>2015</year><volume>313</volume><fpage>677</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.88</pub-id><pub-id pub-id-type="pmid">25688779</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Torre</surname><given-names>MC</given-names></name><name><surname>Toran</surname><given-names>P</given-names></name><name><surname>Serra-Prat</surname><given-names>M</given-names></name><name><surname>Palomera</surname><given-names>E</given-names></name><name><surname>Guell</surname><given-names>E</given-names></name><name><surname>Vendrell</surname><given-names>E</given-names></name><name><surname>Yebenes</surname><given-names>JC</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Almirall</surname><given-names>J</given-names></name></person-group><article-title>Serum levels of immunoglobulins and severity of community-acquired pneumonia</article-title><source>BMJ Open Respir Res</source><year>2016</year><volume>3</volume><fpage>e000152</fpage><pub-id pub-id-type="doi">10.1136/bmjresp-2016-000152</pub-id><pub-id pub-id-type="pmid">27933180</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Apostolidou</surname><given-names>E</given-names></name><name><surname>Lada</surname><given-names>M</given-names></name><name><surname>Perdios</surname><given-names>I</given-names></name><name><surname>Gatselis</surname><given-names>NK</given-names></name><name><surname>Tsangaris</surname><given-names>I</given-names></name><name><surname>Georgitsi</surname><given-names>M</given-names></name><name><surname>Bristianou</surname><given-names>M</given-names></name><name><surname>Kanni</surname><given-names>T</given-names></name><name><surname>Sereti</surname><given-names>K</given-names></name><name><surname>Kyprianou</surname><given-names>MA</given-names></name><name><surname>Kotanidou</surname><given-names>A</given-names></name><name><surname>Armaganidis</surname><given-names>A</given-names></name></person-group><article-title>Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome</article-title><source>Crit Care</source><year>2013</year><volume>17</volume><fpage>R247</fpage><pub-id pub-id-type="doi">10.1186/cc13073</pub-id><pub-id pub-id-type="pmid">24144038</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Justel</surname><given-names>M</given-names></name><name><surname>Socias</surname><given-names>L</given-names></name><name><surname>Almansa</surname><given-names>R</given-names></name><name><surname>Ramirez</surname><given-names>P</given-names></name><name><surname>Gallegos</surname><given-names>MC</given-names></name><name><surname>Fernandez</surname><given-names>V</given-names></name><name><surname>Gordon</surname><given-names>M</given-names></name><name><surname>Andaluz-Ojeda</surname><given-names>D</given-names></name><name><surname>Nogales</surname><given-names>L</given-names></name><name><surname>Rojo</surname><given-names>S</given-names></name><name><surname>Valles</surname><given-names>J</given-names></name><name><surname>Estella</surname><given-names>A</given-names></name><name><surname>Loza</surname><given-names>A</given-names></name><name><surname>Leon</surname><given-names>C</given-names></name><name><surname>Lopez-Mestanza</surname><given-names>C</given-names></name><name><surname>Blanco</surname><given-names>J</given-names></name><name><surname>Berezo</surname><given-names>JA</given-names></name><name><surname>Rosich</surname><given-names>S</given-names></name><name><surname>Cilloniz</surname><given-names>C</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>de Lejarazu</surname><given-names>RO</given-names></name><name><surname>Martin-Loeches</surname><given-names>I</given-names></name><name><surname>Bermejo-Martin</surname><given-names>JF</given-names></name></person-group><article-title>IgM levels in plasma predict outcome in severe pandemic influenza</article-title><source>J Clin Virol</source><year>2013</year><volume>58</volume><fpage>564</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2013.09.006</pub-id><pub-id pub-id-type="pmid">24076102</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrenstein</surname><given-names>MR</given-names></name><name><surname>Notley</surname><given-names>CA</given-names></name></person-group><article-title>The importance of natural IgM: scavenger, protector and regulator</article-title><source>Nat Rev Immunol</source><year>2010</year><volume>10</volume><fpage>778</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1038/nri2849</pub-id><pub-id pub-id-type="pmid">20948548</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Esen</surname><given-names>F</given-names></name><name><surname>Tugrul</surname><given-names>S</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group><article-title>IgM-enriched immunoglobulins in sepsis</article-title><source>Yearbook of intensive care and emergency medicine</source><year>2009</year><publisher-loc>New York</publisher-loc><publisher-name>Springer</publisher-name><fpage>102</fpage><lpage>110</lpage></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rieben</surname><given-names>R</given-names></name><name><surname>Roos</surname><given-names>A</given-names></name><name><surname>Muizert</surname><given-names>Y</given-names></name><name><surname>Tinguely</surname><given-names>C</given-names></name><name><surname>Gerritsen</surname><given-names>AF</given-names></name><name><surname>Daha</surname><given-names>MR</given-names></name></person-group><article-title>Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation</article-title><source>Blood</source><year>1999</year><volume>93</volume><fpage>942</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">9920844</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duerr</surname><given-names>C</given-names></name><name><surname>De Martin</surname><given-names>A</given-names></name><name><surname>Sachet</surname><given-names>M</given-names></name><name><surname>Konrad</surname><given-names>T</given-names></name><name><surname>Baumann</surname><given-names>S</given-names></name><name><surname>Spittler</surname><given-names>A</given-names></name></person-group><article-title>Influence of an immunoglobulin-enriched (IgG, IgA, IgM) solution on activation and immunomodulatory functions of peripheral blood mononuclear cells in a LPS second-hit model</article-title><source>Crit Care</source><year>2011</year><volume>15</volume><issue>Suppl 1</issue><fpage>P244</fpage><pub-id pub-id-type="doi">10.1186/cc9664</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shmygalev</surname><given-names>S</given-names></name><name><surname>Damm</surname><given-names>M</given-names></name><name><surname>Knels</surname><given-names>L</given-names></name><name><surname>Strassburg</surname><given-names>A</given-names></name><name><surname>Wunsche</surname><given-names>K</given-names></name><name><surname>Dumke</surname><given-names>R</given-names></name><name><surname>Stehr</surname><given-names>SN</given-names></name><name><surname>Koch</surname><given-names>T</given-names></name><name><surname>Heller</surname><given-names>AR</given-names></name></person-group><article-title>IgM-enriched solution BT086 improves host defense capacity and energy store preservation in a rabbit model of endotoxemia</article-title><source>Acta Anaesthesiol Scand</source><year>2016</year><volume>60</volume><fpage>502</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1111/aas.12652</pub-id><pub-id pub-id-type="pmid">26555358</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welte</surname><given-names>T</given-names></name><name><surname>Dellinger</surname><given-names>RP</given-names></name><name><surname>Ebelt</surname><given-names>H</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Opal</surname><given-names>SM</given-names></name><name><surname>Schliephake</surname><given-names>DE</given-names></name><name><surname>Wartenberg-Demand</surname><given-names>A</given-names></name><name><surname>Werdan</surname><given-names>K</given-names></name><name><surname>Loffler</surname><given-names>K</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name></person-group><article-title>Concept for a study design in patients with severe community-acquired pneumonia: a randomised controlled trial with a novel IGM-enriched immunoglobulin preparation&#x02014;the CIGMA study</article-title><source>Respir Med</source><year>2015</year><volume>109</volume><fpage>758</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2015.03.008</pub-id><pub-id pub-id-type="pmid">25887136</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Welte T, Almirall J, Ayesteran JI, Artigas A, Nuding S, Rodriguez G, Ferrer R, Shankar-Hari M, Alvarez Lerma F, Riessen R, Sirvent J-M, Kluge S, Lapp H, Wobker G, Zacharowksi K, Bonastre Mora J, Wartenburg-Demand A, Langohr P, Daelken B, Torres A (2018) Reduction in mortality with a novel polyclonal antibody preparation in patients with severe community-acquired pneumonia. <ext-link ext-link-type="uri" xlink:href="https://www.escmid.org/escmid_publications/escmid_elibrary/?q=welte&#x00026;id=2173&#x00026;L=0&#x00026;tx_solr%5Bsort%5D=relevance%2Basc&#x00026;tx_solr%5Bfilter%5D%5B0%5D=main_filter_eccmid%253Atrue&#x00026;tx_solr%5Bfilter%5D%5B1%5D=pub_date%253A201701010000-201712312359&#x00026;x=0&#x00026;y=0">https://www.escmid.org/escmid_publications/escmid_elibrary/?q=welte&#x00026;id=2173&#x00026;L=0&#x00026;tx_solr%5Bsort%5D=relevance%2Basc&#x00026;tx_solr%5Bfilter%5D%5B0%5D=main_filter_eccmid%253Atrue&#x00026;tx_solr%5Bfilter%5D%5B1%5D=pub_date%253A201701010000-201712312359&#x00026;x=0&#x00026;y=0</ext-link>. Accessed 26 Jan 2018</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandell</surname><given-names>LA</given-names></name><name><surname>Wunderink</surname><given-names>RG</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Bartlett</surname><given-names>JG</given-names></name><name><surname>Campbell</surname><given-names>GD</given-names></name><name><surname>Dean</surname><given-names>NC</given-names></name><name><surname>Dowell</surname><given-names>SF</given-names></name><name><surname>File</surname><given-names>TM</given-names><suffix>Jr</suffix></name><name><surname>Musher</surname><given-names>DM</given-names></name><name><surname>Niederman</surname><given-names>MS</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Whitney</surname><given-names>CG</given-names></name></person-group><article-title>Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults</article-title><source>Clin Infect Dis</source><year>2007</year><volume>44</volume><issue>Suppl 2</issue><fpage>S27</fpage><lpage>S72</lpage><pub-id pub-id-type="doi">10.1086/511159</pub-id><pub-id pub-id-type="pmid">17278083</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenfeld</surname><given-names>DA</given-names></name><name><surname>Bernard</surname><given-names>GR</given-names></name></person-group><article-title>Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>1772</fpage><lpage>1777</lpage><pub-id pub-id-type="doi">10.1097/00003246-200208000-00016</pub-id><pub-id pub-id-type="pmid">12163791</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604&#x02013;612</mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becze</surname><given-names>Z</given-names></name><name><surname>Molnar</surname><given-names>Z</given-names></name><name><surname>Fazakas</surname><given-names>J</given-names></name></person-group><article-title>Can procalcitonin levels indicate the need for adjunctive therapies in sepsis?</article-title><source>Int J Antimicrob Agents</source><year>2015</year><volume>46</volume><issue>Suppl 1</issue><fpage>S13</fpage><lpage>S18</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2015.11.002</pub-id><pub-id pub-id-type="pmid">26621136</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Oxford University Hospitals NHS Foundation Trust (2017) Immunoglobulins. <ext-link ext-link-type="uri" xlink:href="http://www.ouh.nhs.uk/immunology/diagnostic-tests/tests-catalogue/immunoglobulins.aspx">http://www.ouh.nhs.uk/immunology/diagnostic-tests/tests-catalogue/immunoglobulins.aspx</ext-link>. Accessed 22 Mar 2017</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Torre</surname><given-names>MC</given-names></name><name><surname>Bolibar</surname><given-names>I</given-names></name><name><surname>Vendrell</surname><given-names>M</given-names></name><name><surname>de Gracia</surname><given-names>J</given-names></name><name><surname>Vendrell</surname><given-names>E</given-names></name><name><surname>Rodrigo</surname><given-names>MJ</given-names></name><name><surname>Boquet</surname><given-names>X</given-names></name><name><surname>Torrebadella</surname><given-names>P</given-names></name><name><surname>Yebenes</surname><given-names>JC</given-names></name><name><surname>Serra-Prat</surname><given-names>M</given-names></name><name><surname>Rello</surname><given-names>J</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Almirall</surname><given-names>J</given-names></name></person-group><article-title>Serum immunoglobulins in the infected and convalescent phases in community-acquired pneumonia</article-title><source>Respir Med</source><year>2013</year><volume>107</volume><fpage>2038</fpage><lpage>2045</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2013.09.005</pub-id><pub-id pub-id-type="pmid">24084059</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bermejo-Martin</surname><given-names>JF</given-names></name><name><surname>Rodriguez-Fernandez</surname><given-names>A</given-names></name><name><surname>Herran-Monge</surname><given-names>R</given-names></name><name><surname>Andaluz-Ojeda</surname><given-names>D</given-names></name><name><surname>Muriel-Bombin</surname><given-names>A</given-names></name><name><surname>Merino</surname><given-names>P</given-names></name><name><surname>Garcia-Garcia</surname><given-names>MM</given-names></name><name><surname>Citores</surname><given-names>R</given-names></name><name><surname>Gandia</surname><given-names>F</given-names></name><name><surname>Almansa</surname><given-names>R</given-names></name><name><surname>Blanco</surname><given-names>J</given-names></name></person-group><article-title>Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis</article-title><source>J Intern Med</source><year>2014</year><volume>276</volume><fpage>404</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1111/joim.12265</pub-id><pub-id pub-id-type="pmid">24815605</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalmers</surname><given-names>JD</given-names></name><name><surname>Singanayagam</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>AT</given-names></name></person-group><article-title>C-reactive protein is an independent predictor of severity in community-acquired pneumonia</article-title><source>Am J Med</source><year>2008</year><volume>121</volume><fpage>219</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2007.10.033</pub-id><pub-id pub-id-type="pmid">18328306</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloos</surname><given-names>F</given-names></name><name><surname>Marshall</surname><given-names>JC</given-names></name><name><surname>Dellinger</surname><given-names>RP</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Gutierrez</surname><given-names>G</given-names></name><name><surname>Rivers</surname><given-names>E</given-names></name><name><surname>Balk</surname><given-names>RA</given-names></name><name><surname>Laterre</surname><given-names>PF</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Reinhart</surname><given-names>K</given-names></name><name><surname>Brunkhorst</surname><given-names>FM</given-names></name></person-group><article-title>Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study</article-title><source>Crit Care</source><year>2011</year><volume>15</volume><fpage>R88</fpage><pub-id pub-id-type="doi">10.1186/cc10087</pub-id><pub-id pub-id-type="pmid">21385367</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Povoa</surname><given-names>P</given-names></name><name><surname>Coelho</surname><given-names>L</given-names></name><name><surname>Almeida</surname><given-names>E</given-names></name><name><surname>Fernandes</surname><given-names>A</given-names></name><name><surname>Mealha</surname><given-names>R</given-names></name><name><surname>Moreira</surname><given-names>P</given-names></name><name><surname>Sabino</surname><given-names>H</given-names></name></person-group><article-title>C-reactive protein as a marker of infection in critically ill patients</article-title><source>Clin Microbiol Infect</source><year>2005</year><volume>11</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2004.01044.x</pub-id><pub-id pub-id-type="pmid">15679483</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ugarte</surname><given-names>H</given-names></name><name><surname>Silva</surname><given-names>E</given-names></name><name><surname>Mercan</surname><given-names>D</given-names></name><name><surname>De Mendonca</surname><given-names>A</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group><article-title>Procalcitonin used as a marker of infection in the intensive care unit</article-title><source>Crit Care Med</source><year>1999</year><volume>27</volume><fpage>498</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1097/00003246-199903000-00024</pub-id><pub-id pub-id-type="pmid">10199528</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bel</surname><given-names>J</given-names></name><name><surname>Hausfater</surname><given-names>P</given-names></name><name><surname>Chenevier-Gobeaux</surname><given-names>C</given-names></name><name><surname>Blanc</surname><given-names>FX</given-names></name><name><surname>Benjoar</surname><given-names>M</given-names></name><name><surname>Ficko</surname><given-names>C</given-names></name><name><surname>Ray</surname><given-names>P</given-names></name><name><surname>Choquet</surname><given-names>C</given-names></name><name><surname>Duval</surname><given-names>X</given-names></name><name><surname>Claessens</surname><given-names>YE</given-names></name></person-group><article-title>Diagnostic accuracy of C-reactive protein and procalcitonin in suspected community-acquired pneumonia adults visiting emergency department and having a systematic thoracic CT scan</article-title><source>Crit Care</source><year>2015</year><volume>19</volume><fpage>366</fpage><pub-id pub-id-type="doi">10.1186/s13054-015-1083-6</pub-id><pub-id pub-id-type="pmid">26472401</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantal</surname><given-names>J</given-names></name></person-group><article-title>Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk</article-title><source>Am J Nephrol</source><year>2013</year><volume>38</volume><fpage>275</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1159/000354893</pub-id><pub-id pub-id-type="pmid">24051350</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacci</surname><given-names>MR</given-names></name><name><surname>Leme</surname><given-names>RC</given-names></name><name><surname>Zing</surname><given-names>NP</given-names></name><name><surname>Murad</surname><given-names>N</given-names></name><name><surname>Adami</surname><given-names>F</given-names></name><name><surname>Hinnig</surname><given-names>PF</given-names></name><name><surname>Feder</surname><given-names>D</given-names></name><name><surname>Chagas</surname><given-names>AC</given-names></name><name><surname>Fonseca</surname><given-names>FL</given-names></name></person-group><article-title>IL-6 and TNF-alpha serum levels are associated with early death in community-acquired pneumonia patients</article-title><source>Braz J Med Biol Res</source><year>2015</year><volume>48</volume><fpage>427</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1590/1414-431X20144402</pub-id><pub-id pub-id-type="pmid">25714883</pub-id></element-citation></ref></ref-list></back></article>